



ASH 2023

65th ASH Annual Meeting and Exposition

December 9–12, 2023
San Diego, US



TOP ABSTRACTS

To help navigate the exciting content being presented at the 65th ASH Annual Meeting and Exposition, we have provided recommendations for the top abstracts to look out for in GvHD.

ASH 2023: Top abstracts in GvHD

December 9–12, 2023

GvHD prophylaxis and early phase trials	
Abstract	Title
1 View	Safety and efficacy of axatilimab at 3 different doses in patients with chronic graft-versus-host disease (AGAVE-201)
59 View	TIM-3 inhibitor sabatolimab for patients with acute myeloid leukemia (AML) with measurable residual disease (MRD) Detected after Allogeneic Stem Cell transplantation (AlloSCT): preliminary findings from the phase Ib/II stimulus-AML2 study
237 View	Relapse incidence post unrelated allogeneic stem cell transplantation with post-transplant cyclophosphamide (PTCy) versus conventional anti-graft versus host disease prophylaxis in patients with acute myeloid leukemia: a study on behalf of the acute leukemia working party of the european society for blood and marrow transplantation
649 View	Effective prevention of steroid-requiring chronic graft-vs.-host disease with B cell depletion: a randomized, placebo-controlled trial
651 View	Itacitinib for prevention of graft-versus-host disease and cytokine release syndrome with T-cell replete peripheral blood haploidentical transplantation
653 View	Maintenance ruxolitinib is associated with low rates of chronic Gvhd requiring systemic treatment in older adults with AML/MDS undergoing allogeneic HCT: results of a phase II multicenter trial
775 View	A phase II multicenter trial of ruxolitinib to treat bronchiolitis obliterans syndrome after allogeneic hematopoietic cell transplantation
777 View	Topical ruxolitinib for chronic cutaneous GvHD: promising results of a phase 2 clinical trial
2103 View	Updated findings of a phase II study of ruxolitinib pre-, during- and post-hematopoietic stem cell transplantation for patients with primary or secondary myelofibrosis
2179 View	Post-transplant cyclophosphamide or ATG as Gvhd prophylaxis in mismatched unrelated stem cell transplantation? – a registry analysis by the EBMT transplant complications working party
2181 View	Post-transplant cyclophosphamide, tacrolimus or cyclosporine a and mycophenolate mofetil compared to anti-thymocyte globulin, tacrolimus or cyclosporine a and methotrexate combinations as graft-versus-host disease prophylaxis post allogeneic stem cell transplantation from sibling and unrelated donors in patients with acute myeloid leukemia: a study on behalf of the acute leukemia working party of the European Society for Blood and Marrow Transplantation

4947 View	A multicentre, randomized, double-blinded, phase 2b study evaluating the efficacy and safety of MaaT033, an oral, pooled microbiome ecosystem therapy in patients undergoing allogeneic hematopoietic cell transplantation to improve overall survival: the Phoebus trial
4975 View	Post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis in HLA-matched and haploidentical donor transplants for patients with hodgkin disease: a comparative study of the LWP EBMT
3551 View	A prospective randomized clinical trial comparing a calcineurin-free Gvhd prophylaxis regimen with post-transplant cyclophosphamide and abatacept to methotrexate and tacrolimus

Late phase trials

Abstract	Title
654 View	Ruxolitinib in patients with chronic graft-versus-host disease: 3-year final analysis of efficacy and safety From the phase III REACH3 study

Novel therapies

Abstract	Title
3553 View	Pooled fecal allogeneic microbiotherapy for refractory gastrointestinal acute graft-versus-host disease: results from early access program in Europe
3556 View	A prospective, multi-center, randomized, controlled clinical trial to explore the role of mesenchymal stem cells in preventing graft versus host disease
3563 View	Efficacy and safety of processed amniotic fluid (paf) drops for the treatment of ocular chronic graft-versus-host disease
3569 View	Efficacy and safety of fecal microbiota transplantation in the treatment of chronic steroid-refractory graft-versus-host disease after hematopoietic stem cell transplantation
4927 View	Real-world data suggest effectiveness of allogeneic mesenchymal stromal (MSC-FFM) cells in ruxolitinib-refractory acute graft-versus-host disease
4977 View	UM171 expanded cord blood transplantation outcomes compare favorably to all different stem cell sources: an EBMT registry case-control analysis

Risk stratification	
Abstract	Title
479 View	Machine learning validates risk biomarkers of chronic graft-versus-host disease in 936 patients from BMT CTN 0201 & 1202 cohorts
652 View	Systematic prediction of minor histocompatibility antigens to inform GvHD outcomes after allogeneic stem cell transplantation
2191 View	The area under tacrolimus concentrations on Day 14-28 is the independent predictor of the development of chronic Gvhd in patients without severe acute Gvhd after unrelated allogeneic HSCT
2196 View	Artificial intelligence (AI) based, machine learning (ML) predicting the individual absolute risk of acute graft versus host disease (aGvHD) in a retrospective international cohort
3576 View	The MAGIC algorithm probability predicts long-term outcomes and treatment response to second-line therapy for acute Gvhd

Advances in disease biology and clinical trial methodology	
Abstract	Title
Scientific Symposia View	Microbiota's impact on stem cell transplant outcomes and GVHD
776 View	Flares of acute graft-versus-host disease: Mount Sinai Acute Gvhd International Consortium (MAGIC) study
779 View	A Day 14 endpoint for acute Gvhd clinical trials
2043 View	Intestinal geographical pattern of gut microbiome and metabolites identifies novel regulators of graft-versus-host disease



ASH 2023

Follow us on X to keep up to date
with the latest from the congress

@gvhd_hub

#ASH23

View all @gvhd_hub_ tweets from #ASH23



Brought to you by



**Scientific
Education
Support**